Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Rheumatology

Systemic Lupus (SLE)

Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus

Seminars in Arthritis and Rheumatism | Sep 30, 2021 Systemic Lupus (SLE)

The high prevalence of abnormal MRI findings in non-neuropsychiatric patients with persistently positive antiphospholipid antibodies

Rheumatology | Sep 29, 2021 Systemic Lupus (SLE)

The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus

Lupus | Sep 22, 2021 Systemic Lupus (SLE)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus

Rheumatology | Sep 20, 2021 Systemic Lupus (SLE)

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: A phase 2, randomised, double-blind, placebo-controlled study

Rheumatology | Sep 14, 2021 Systemic Lupus (SLE)

Cognitive function trajectories in association with the depressive symptoms trajectories in systemic lupus erythematosus over time

Arthritis Care & Research | Sep 09, 2021 Systemic Lupus (SLE)

Racial differences in contraception encounters and dispensing among female Medicaid beneficiaries with systemic lupus erythematosus

Arthritis Care & Research | Sep 09, 2021 Systemic Lupus (SLE)

Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double‐blind, placebo‐controlled trial

Arthritis & Rheumatology | Sep 01, 2021 Systemic Lupus (SLE)

Accelerated atherosclerosis in systemic lupus erythematosus: Role of fibroblast growth factor 23- phosphate axis

International Journal of Nephrology and Renovascular Disease | Aug 31, 2021 Systemic Lupus (SLE)

Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Annals of Rheumatic Diseases | Aug 21, 2021 Systemic Lupus (SLE)

« Prev 1 2 3 4 5 6 … 56 Next »

Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus

The high prevalence of abnormal MRI findings in non-neuropsychiatric patients with persistently positive antiphospholipid antibodies

The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: A phase 2, randomised, double-blind, placebo-controlled study

Cognitive function trajectories in association with the depressive symptoms trajectories in systemic lupus erythematosus over time

Racial differences in contraception encounters and dispensing among female Medicaid beneficiaries with systemic lupus erythematosus

Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double‐blind, placebo‐controlled trial

Accelerated atherosclerosis in systemic lupus erythematosus: Role of fibroblast growth factor 23- phosphate axis

Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Top Foods to Combat Winter Illness

Pulmonary Embolism: MCQs Challenge

The Role of Nutrition in Enhancing Fertility for Men and Women

Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus

The high prevalence of abnormal MRI findings in non-neuropsychiatric patients with persistently positive antiphospholipid antibodies

The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: A phase 2, randomised, double-blind, placebo-controlled study

Cognitive function trajectories in association with the depressive symptoms trajectories in systemic lupus erythematosus over time

Racial differences in contraception encounters and dispensing among female Medicaid beneficiaries with systemic lupus erythematosus

Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double‐blind, placebo‐controlled trial

Accelerated atherosclerosis in systemic lupus erythematosus: Role of fibroblast growth factor 23- phosphate axis

Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Top Foods to Combat Winter Illness

Pulmonary Embolism: MCQs Challenge

The Role of Nutrition in Enhancing Fertility for Men and Women

Select Specialty

Select Topic